Twist Bioscience TWST
United StatesHealthcare · BiotechnologyUSD
133.75 USD (−14.1%)
12 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Twist Bioscience is a biotechnology company that manufactures synthetic DNA products at scale, such as genes, antibody libraries, and sequencing tools, selling to customers in the pharmaceutical, agrochemical, and diagnostics sectors.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Strong growth8.5
- ✕Little or no dividend0.5
- ✕Demanding valuation0.8
- ✕Unfavourable risk and backdrop0.9
AI analysis
bottom line, main risk, context and newsHold only for investors with high risk tolerance and a long horizon; profitability and valuation do not justify new entry in the short term.
Twist Bioscience shows revenue growth of 23.20% and exceptional momentum (307.89% over 12 months), but it is still unprofitable (operating margin of -30.65%) and its valuation is very demanding (FCF yield of -0.63), making it a high-risk bet on distant future cash flows.
The main risk is the lack of sustained profitability: with an operating margin of -30.65% and an ROIC of -22.81%, the company depends on external financing and on its revenue growth translating into profits before market confidence runs out.
Context and risks
The company operates in the biotechnology sector in the US, where regulatory risk is inherent to the business model (FDA approvals, clinical trials). Although the country has solid institutions, exposure to regulatory approval of its products is a material risk that no financial metric captures.
Is Twist Bioscience stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 599% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 21.9 | 4.1 | +433% |
| Price / sales | 23.9 | 3.4 | +599% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 133.75 USD, −14.1% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 2.6 (sector 5.5), Growth 8.5 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −207.1
- EV / EBITDA
- −84.2
- Price / book
- 21.9
- Price / sales
- 23.9
- Market cap
- 10.3B USD
- Enterprise value
- 9.7B USD
Profitability
- ROE
- −29.6%
- ROA
- −13.1%
- ROIC (approx.)
- −22.8%
- Gross margin
- 52.0%
- Operating margin
- −30.6%
- Net margin
- −31.7%
- Free cash flow
- −64.8M USD
- FCF yield
- −0.6%
Solvency
- Total debt
- 108.6M USD
- Net debt
- −58.2M USD
- Cash
- 166.8M USD
- EBITDA
- −115.3M USD
- Net debt / EBITDA
- 0.51
- Debt / equity
- 24.36
- Current ratio
- 2.67
- Quick ratio
- 1.98
Growth
- Revenue growth
- +23.2%
- EPS (TTM)
- −2.23 USD
- EPS (forward)
- −0.75 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 2.19
- Analyst consensus
- Buy (12)
- Target price
- 133.75 USD
- 52-week range
- 23.30 – 219.71
Recent news
All TWST news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Twist Bioscience
Is Twist Bioscience stock cheap or expensive?
On Price / sales, it trades 599% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 133.75 USD, −14.1% versus the price. This is not investment advice.
What score does Twist Bioscience get on MeridIAn Screener?
It scores 3.6 out of 10, rank 2,024 of 2,130 (better than 5% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Twist Bioscience worth on the stock market?
Its market capitalisation is 10.3B USD and its enterprise value, debt included, is 9.7B USD.
How much debt does Twist Bioscience have?
It has more cash than debt: net cash of 58.2M USD.
Does Twist Bioscience pay a dividend?
It pays no dividend, or almost none.
How has Twist Bioscience stock performed over the last year?
It has risen 399.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 23.30 and 219.71 USD. Past performance does not guarantee future results.
What do analysts think of Twist Bioscience?
12 analysts cover it; their average recommendation is “Buy” and their average target is 133.75 USD (−14.1% versus the price). It is an estimate, not market data.